CAI vs LRCX · rev $812.0M vs P/E 71, rev $23.23B
Caris Life Sciences, Inc. Common Stock (CAI) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
CAI currently screens at market cap $5.22B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the CAI and LRCX stock pages for the full models.
Not investment advice.